




Supplementary Figure S1. Ligplot analysis of bovine TLR2 dimeric forms.




Supplementary Figure S2. The best docking mode of PAMs and TLR2 dimeric forms.



Supplementary Figure S3. RMSD plot for protein backbone for two systems (bTLR2/1-PAM3 and bTLR2/6-PAM2) during 150 ns MD simulation.



Supplementary Figure S4. Extension of MD simulation time to 300 ns for enhanced system stability over a longer duration. A) Analysis of the Root Mean Square Deviation (RMSD) of the protein backbone in the TLR2 heterodimer system. B) Analysis of the center of mass distance between TLRs and agonists.



Supplementary Figure S5. Ligplot analysis illustrating residues involved in PAMs interactions with TLRs, with hydrophobic residues playing a dominant role. Green outlined boxes indicate polar residue of TLR2 involved in the interaction with peptide chain of PAMs. Blue outlined boxes indicate polar residue of TLR1 involved in the interaction with peptide chain of PAMs. Red outlined boxes indicate polar residue of TLR6 involved in the interaction with peptide chain of PAMs. Green semi-transparent boxes indicate polar residue of TLR2 involved in the interaction with acylated lipid chain of PAMs. Blue semi-transparent boxes indicate polar residue of TLR1 involved in the interaction with acylated lipid chain of PAMs.


TLR2 Human - Bovine

sp Q06603 TLR2_HUMAN	RCVNLQALVLTSGINTIIEEDSFSSLGSLHLDLSYNYLSNLSSSWFKPLSSITFLNLLGNPYKTLGETSLFS	146
sp Q95LA9 TLR2_BOVIN	RCVNLKTLRLGANEIHTIVEEDSFHRLNLEYLDLSYNYLSNLSSSWFRSLYVLFKFLNLLGNLYKTLGETSLFS	146
O6603:Signal		
sp Q06603 TLR2_HUMAN	HETKQILRVGNMDTETKQRKDFAGLTFLLEELEDASDLOSVEPKSLKSIQNVSHLILHMKQHILLETIVD	219
sp Q95LA9 TLR2_BOVIN	HEPNLRTLKVGNSNSFTEHEKDFGTGLTFLEELEISAQNLQIIVPKSLKSIQNI SHLILHLKQPIILLVDILVD	219
O6603:Signal		
sp Q06603 TLR2_HUMAN	VTSSVECLELRDIDDTTFHESELSTGETNSLIKKFTFRNVKITDESDFQVMKILNQISGLLELEFDDCTLNGV	292
sp Q95LA9 TLR2_BOVIN	IYSSLDCEFLRDTNLHTFHESEASISEMSTSVKKLIFRNVQFTDESDFVEVVKLFNYVSGILEVEFDDCTHDG	292
O6603:Signal		
sp Q06603 TLR2_HUMAN	GNFRASDNDRIDPGKVETLTIRRLHIPRFYLFYDLSTLYSLTERVKRITVENSKVFLVPCLLSQHLKSLEYL	365
sp Q95LA9 TLR2_BOVIN	GDFRALSRLDIRHLGNVETLTIRKLHIPQFLEFHDLSIYPLTGRYKRVITENSKVFLVPCLLSQHLKSLEYL	365
O6603:Signal		
sp Q06603 TLR2_HUMAN	DLSENLMVEEYLNKSACEAWPFLQTLVLRQNHLSLEKTGELLTLKNTNIDISKNSFHSMPETCQWPEKM	438
sp Q95LA9 TLR2_BOVIN	DLSENLMSEETLNKSACKDAWFFLQTLVLRQNRKLSLEKTGELLTLLENLNNIDISKNNFLSMPETCQWRGKM	438
O6603:Signal		
sp Q06603 TLR2_HUMAN	KVLNLSSTRIHSEVTGCIPTLEILDVSNNNLDSFSLNLPQLKELYISRNKMLTPDASLLPMLLVKISRNA	511
sp Q95LA9 TLR2_BOVIN	NKLNLSSTRIHSLTQCLPQTLLEILDVSNNNLDSFSLNLPQLKELYISRNKMLTPDASFLPVLSVMRISRNI	511
O6603:Signal		
sp Q06603 TLR2_HUMAN	TTFSEQLDSFHTLKTLEAGGNFICSCFELSFTQEQQALAKVLIWDPANVLCDSPSHVGRQQVQDVRLSVSE	584
sp Q95LA9 TLR2_BOVIN	NTFSKEQLDSFQQKTLEAGGNFICSCDFLSFTQEQQALGRVLDWPDYRCDSPSHVGRQVRQDARLSLS	584
O6603:Signal		
sp Q06603 TLR2_HUMAN	CHRTLVSGMCCALFLLLLTGVLCRHFHGLWYMKMMWAWLQAKRKPAPRRNICYDAFVSYSERDAYWVEN	657
sp Q95LA9 TLR2_BOVIN	CHRAAVVSAACCALFLLLLTGVLCRHFHGLWYMKMMWAWLQAKRKPAPRRDICYDAFVSYSERDSYWVEN	657
O6603:Signal		
sp Q06603 TLR2_HUMAN	LMVQELFNPPFKLCLHKRDFIPGKWIIDNIDISIEKSHKTVFVLSENFVKSEWCKYELDFSHRFLFDENND	730
sp Q95LA9 TLR2_BOVIN	LMVQELEHFNPPFKLCLHKRDFIPGKWIIDNIDISIEKSHKTVFVLSENFVKSEWCKYELDFSHRFLFDENND	730
O6603:Signal		


TLR2 Mouse - Bovine

sp Q9QUN7 TLR2_MOUSE	ACANLQVLIKSSRINTIEGDAFYSLSLEHLDLSNDHLSLSSSWFGPLSSLYKYNLMGNPYQTIGVTSFLP	146
sp Q95LA9 TLR2_BOVIN	RCVNLKTLRLGANEIHTIVEEDSFHRLNLEYLDLSYNYLSNLSSSWFRSLYVLFKFLNLLGNLYKTLGETSLFS	146
Q9QUN7:Signal		
sp Q9QUN7 TLR2_MOUSE	NLTNLQTLRIQNVETFSERRIDFAGLTSENELETKALSRNYQSQSLKSTRDTHMLTLEHSESALLETIFAD	219
sp Q95LA9 TLR2_BOVIN	HLPNLRLLKVGNSNSFTEHEKDFGTGLTFLEELEISAQNLQIIVPKSLKSIQNI SHLILHLKQPIILLVDILVD	219
Q9QUN7:Signal		
sp Q9QUN7 TLR2_MOUSE	ILSSVRYLELRDNLARFQFSPLPVDEVSSPMKKLAFRGSVLTDESFNELLKLLRYILELSEVEFDDCTLNGL	292
sp Q95LA9 TLR2_BOVIN	IYSSLDCEFLRDTNLHTFHESEASISEMSTSVKKLIFRNVQFTDESDFVEVVKLFNYVSGILEVEFDDCTHDG	292
Q9QUN7:Signal		
sp Q9QUN7 TLR2_MOUSE	GDENPSESDEVSELGKVETVTIRRLHIPQFYLEFYDLSTVYSLLEKVKRITVENSKVFLVPCFSFQHLKSLEYL	365
sp Q95LA9 TLR2_BOVIN	GDFRALSRLDIRHLGNVETLTIRKLHIPQFLEFHDLSIYPLTGRYKRVITENSKVFLVPCLLSQHLKSLEYL	365
Q9QUN7:Signal		
sp Q9QUN7 TLR2_MOUSE	DLSENLMVEEYLNKSACKCAWPSLQTLVLSQNHRSMQKTGEILLTLKNTSLDISRNI FHPMPDSQWPEKM	438
sp Q95LA9 TLR2_BOVIN	DLSENLMSEETLNKSACKDAWFFLQTLVLRQNRKLSLEKTGELLTLLENLNNIDISKNNFLSMPETCQWPGKM	438
Q9QUN7:Signal		
sp Q9QUN7 TLR2_MOUSE	RFLNLSSTGIRVVKTCIPQTLLEVLDVSNNNLDSFSLFPRQLQELYISRNKMLTPDASFLPVLLVMKIRENAV	511
sp Q95LA9 TLR2_BOVIN	KQLNLSSTRIHSLTQCLPQTLLEILDVSNNNLDSFSLNLPQLKELYISRNKMLTPDASFLPVLSVMRISRNI	511
Q9QUN7:Signal		
sp Q9QUN7 TLR2_MOUSE	STFSKQDQSGFPKLETLAAGDNHFCSCCELLSFTMETPALAQILVDWPDSEVLCDSPPRLHGHRLQDARPSVLE	584
sp Q95LA9 TLR2_BOVIN	NTFSKEQLDSFQQKTLEAGGNFICSGDFLSFTQEQQALGRVLDWPDYRCDSPSHVGRQVRQDARLSLS	584
Q9QUN7:Signal		
sp Q9QUN7 TLR2_MOUSE	CHQAAVLSGVCCALLLEILLVGA LCHHFHGLWYLRMMWAWLQAKRKPAPRRNICYDAFVSYSERDSYWVEN	657
sp Q95LA9 TLR2_BOVIN	CHRAAVVSAACCALFLLLLTGVLCRHFHGLWYMKMMWAWLQAKRKPAPRRDICYDAFVSYSERDSYWVEN	657
Q9QUN7:Signal		
sp Q9QUN7 TLR2_MOUSE	LMVQLENSDPPFKLCLHKRDFIPGKWIIDNIDISIEKSHKTVFVLSENFVKSEWCKYELDFSHRFLFDENND	730
sp Q95LA9 TLR2_BOVIN	LMVQELEHFNPPFKLCLHKRDFIPGKWIIDNIDISIEKSHKTVFVLSENFVKSEWCKYELDFSHRFLFDENND	730
Q9QUN7:Signal		


Supplementary Figure S6. Protein sequence alignment comparing human TLR2 with bovine TLR2, and mouse TLR2 with bovine TLR2.




Supplementary Figure S7. RMSD of antagonist and bovine TLRs during 100 ns MD simulation. The RMSD analysis indicates a lower deviation in the bound states compared to the unbound states, underscoring the interaction between the antagonist and TLR2 and TLR1. However, this difference is not significant for antagonist-TLR6 complexes.




Supplementary Figure S8. The distance analysis between one Oxygen atoms of antagonist and one Carbon alpha of one of the main residues in the main binding site of bovine TLRs during 150 ns MD simulation.




Supplementary Figure S9. RDF analysis for antagonist and the main binding site of TLRs in monomeric forms.




Supplementary Figure S10. RDF analysis for antagonist and the main binding site of TLRs in dimeric forms.




Supplementary Figure S11. Asn residues glycosylated in human and mouse TLRs.




Supplementary Figure S12. Comparison of Alphafold and SWISS-MODEL programs for generating bovine TLRs protein structures. The structural alignment reveals a remarkably high similarity between the protein structures generated by both programs. While the Ramachandran plots exhibit similarities for both Alphafold and SWISS-MODEL, notable distinctions emerge. Interestingly, in SWISS-MODEL structures, the overall quality factor surpasses that of Alphafold. Specifically, for TLR1, the quality factors are 86.7 and 85.5 for SWISS-MODEL and Alphafold, respectively. Similarly, for TLR2, the values are 85.33 (SWISS-MODEL) and 83.17 (Alphafold). Lastly, for TLR6, the quality factors stand at 87.8 and 84.32 for SWISS-MODEL and Alphafold, respectively.




Supplementary Figure S13. Superimposition of extracted PAM3 and PAM2 crystal structures (coordinates extracted from human and mouse TLR2 heterodimers) shown in red, with their docked conformers in cyan, aligned to bovine TLRs.



Supplementary Figure S14. Superimposition of PAM3 and PAM2 crystal structure (blue) with its docked conformer (green).



Supplementary Figure S15. Replication analysis for ensuring data reproducibility. The figure illustrates the result of two replicas in our simulation system, conducted to validate the reproducibility of data. The experiments were specifically carried out for bovine TLRs and antagonist systems specifically conducted to the center of mass between TLRs and antagonist. The consistent results across the replica experiments affirm the reliability and reproducibility of the data obtained.



Supplementary Figure S16. The calculated correlation coefficient (R^2) demonstrates the relationship between the binding free energy, determined through MM/PBSA, and the experimental K_D and K_d data. These results affirm the reliability and validity of the MD and MM/PBSA outcomes.

Supplementary Table S1. Ramachandran analysis of TLR structures in three species. This table provides the percentage of residues within favored, allowed, and disallowed regions for TLR structures.

Region	Region colour	<i>bTLR2</i>	<i>hTLR2</i>	<i>mTLR2</i>	<i>bTLR1</i>	<i>hTLR1</i>	<i>mTLR1</i>	<i>bTLR6</i>	<i>hTLR6</i>	<i>mTLR6</i>
Residues in most favoured regions (A, B, L)	Red	82.60%	80.10%	81.30%	79.80%	79.60%	82.40%	77.80%	85.30%	82.90%
Residues in additional allowed regions (a, b, l, p)	Yellow	16.80%	17.50%	17.30%	19.10%	19.40%	17.60%	20%	15%	15.50%
Residues in generously allowed regions (~a, ~b, ~l, ~p)	Pale yellow	0.40%	2.20%	1.40%	1%	1%	0%	1.60%	0.00%	1.70%
Residues in disallowed regions	White	0.20%	0.20%	0%	0.10%	0%	0%	0.60%	0.20%	0%
		99.8 % (allowed) 0.2 % (disallowed)	99.8 % (allowed) 0.2 % (disallowed)	100 % (allowed)	99.9 % (allowed) 0.1% (disallowed)	100 % (allowed)	100 % (allowed)	99.4 % (allowed) 0.6 % (disallowed)	99.8 % (allowed) 0.2 % (disallowed)	100 % (allowed)

Supplementary Table S2. Binding free energies (Kcal/mol) using MM/PBSA method for bTLR dimers in the last 10 ns of the MD simulation.

	In presence of agonist	In absence of agonist	Initial structure from HADDOCK	Avg.	SD
<i>bTLR2 - bTLR1</i>	448.8	420.8	401.4	423.7	19.5
<i>bTLR2 - bTLR6</i>	339.6	239.9	142.3	240.6	80.5

Supplementary Table S3. HADDOCK results for bovine TLR2 dimers.

	HADDOCK score	RMSD	vdW	Electrostatic energy	Desolvation energy	Z-score
TLR2/1	-108.3	1.1	-40.8	-320.6	-3.3	-1.5
TLR2/6	-137.7	0.6	-64.7	-345.1	-4.1	-1

Supplementary Table S4. The type and number of TLRs residues which involved in the interaction with PAMs.

	Total residue number	Non-polar residues	Polar residues	Polar residues in the pocket
<i>bTLR2</i> (TLR2/1-PAM3)	17	12	5	4
<i>hTLR2</i> (TLR2/1-PAM3)	23	19	4	1
<i>bTLR1</i> (TLR2/1-PAM3)	10	5	5	3
<i>hTLR1</i> (TLR2/1-PAM3)	10	6	4	2
<i>bTLR2</i> (TLR2/6-PAM2)	21	13	8	4
<i>mTLR2</i> (TLR2/6-PAM2)	29	22	7	3
<i>bTLR6</i> (TLR2/6-PAM2)	6	3	3	0
<i>mTLR6</i> (TLR2/6-PAM2)	2	1	1	0

Supplementary Table S5. The details of docking for ligands and TLRs protein.

	Grid center (xyz)	Grid number (xyz)	Space (Å)
<i>Human TLR2/1</i>	139 * 4.7 * 26	122 * 110 * 66	0.375
<i>Mouse TLR2/6</i>	81.6 * 82.5 * 48.3	98 * 56 * 66	0.375
<i>Bovine TLR2/1</i>	139 * 4.7 * 26	124 * 110 * 66	0.375
<i>Bovine TLR2/6</i>	81.6 * 82.5 * 48.3	98 * 56 * 66	0.375